Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HBI0101 CART in relapsed or refractory multiple myeloma or AL amyloidosis
MOH_2025-01-21_013864Phase 2Recruiting
- Sponsor
- פרופ' פולינה סטפנסקי
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NXC-201 in multiple myeloma (MM) and light-chain amyloidosis, sponsored by פרופ' פולינה סטפנסקי. Started Jan 2025; status: recruiting.
02
Drugs
NXC-201
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2025-01-21_013864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-21_013864.